ArticleNature communications2022
Depletion of tumor associated macrophages enhances local and systemic platelet-mediated anti-PD-1 delivery for post-surgery tumor recurrence treatment.
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
87 citing papers in PubMed, 180 citations in OpenAlex.
- Lighting up Macrophage Reprogramming Assists Immunosuppressive Niche Modulation in Primary Tumors and Tumor-Draining Lymph Nodes of Breast Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Tumor-educated platelets in cancer diagnostics and prognostics: A critical appraisal and roadmap for clinical translation.International journal of cancer · 2026Review
- Biomaterial-based strategies for postoperative residual tumors: From margin clearance to immune control and tissue repair.Materials today. Bio · 2026Review
- Unexpected strong paramagnetism of hydrogels containing carbon-oxygen double bonds induced by calcium cations.Nature materials · 2026Article
- Mammary organoid-based depot for post-surgical chemotherapy and gland regeneration.Nature biomedical engineering · 2026Article
- Smart hydrogels for overcoming cancer multidrug resistance.Molecular cancer · 2026Review
- Article
- Immunomodulatory Fibrous Scaffold with Dual Enzyme-Mimic Activities Prevents Postsurgical Tumor Recurrence.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Harnessing Anoikis-Related Gene Signatures for Immunotherapy Precision: A Machine Learning-Driven Predictive and Prognostic Model.ACS omega · 2026Article
- Hypoxia-specific metal-organic frameworks combined with lactate immunometabolism regulation augment anti-tumor immunity of HIFU.Materials today. Bio · 2026Article
- Circulating sPD-L1 as a tumor microenvironment-derived biomarker: enhancing diagnostic discrimination accuracy in breast cancer.Cancer immunology, immunotherapy : CII · 2026Article
- Lanatoside C ameliorates DSS-induced colitis with improved intestinal barrier integrity and reduced M1 macrophage polarization.Scientific reports · 2026Article
- Preclinical Nanoparticle Approaches Targeting Tumor-Associated Macrophages in Breast Cancer: From Mechanisms to Therapeutic Strategies.International journal of nanomedicine · 2026Review
- The immune landscape of melanoma microenvironmental crosstalk.Frontiers in immunology · 2026Review
- Platelet-engineered CAR-T cells as adjuvant therapy after cancer surgery.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Melanoma treatment in the era of nanotechnology and precision medicine.Journal of nanobiotechnology · 2025Review
- Prediction model incorporating dynamic changes in serum tumor markers for evaluating the efficacy of neoadjuvant chemotherapy in patients with breast cancer: a retrospective cohort study.European journal of medical research · 2025Article
- Progress in the Application of Marine Polysaccharide Drug Delivery Systems in Tumor Immunotherapy: Multiple Mechanisms and Material Forms.Marine drugs · 2025Review
- Blades and barriers: Oral vaccines for conquering cancers and warding off infectious diseases.Acta pharmaceutica Sinica. B · 2025Review
- Platelets in cancer and immunotherapy: functional dynamics and therapeutic opportunities.Experimental hematology & oncology · 2025Review
27 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
Immunosuppressive cells residing in the tumor microenvironment, especially tumor associated macrophages (TAMs), hinder the infiltration and activation of T cells, limiting the anti-cancer outcomes of immune checkpoint blockade. Here, we report a biocompatible alginate-based hydrogel loaded with Pexidartinib (PLX)-encapsulated nanoparticles that gradually release PLX at the tumor site to block colony-stimulating factor 1 receptors (CSF1R) for depleting TAMs. The controlled TAM depletion creates a favorable milieu for facilitating local and systemic delivery of anti-programmed cell death protein 1 (aPD-1) antibody-conjugated platelets to inhibit post-surgery tumor recurrence. The tumor immunosuppressive microenvironment is also reprogrammed by TAM elimination, further promoting the infiltration of T cells into tumor tissues. Moreover, the inflammatory environment after surgery could trigger the activation of platelets to facilitate the release of aPD-1 accompanied with platelet-derived microparticles binding to PD-1 receptors for re-activating T cells. All these results collectively indicate that the immunotherapeutic efficacy against tumor recurrence of both local and systemic administration of aPD-1 antibody-conjugated platelets could be strengthened by local depletion of TAMs through the hydrogel reservoir.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.